ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
606 Ergebnisse für "mark" unter ETH Entrepreneurship
Stoll, Mark | ETH Zurich
... Stoll, Mark | ETH Zurich Press Enter to activate screen reader mode. Homepage Navigation Search ... chevron_right People profile Stoll, Mark Address ETH Zürich Doctorate at D-USYS Mark Stoll Physik der Böden u ... Stoll, Mark | ETH Zurich ... Stoll, Mark | ETH Zurich Press Enter to activate screen reader mode. Homepage Navigation Search ... Stoll, Mark | ETH Zurich ...
alterswohnungen-seefeldstrasse-mark-ammann – Open Plans
... alterswohnungen-seefeldstrasse- mark-ammann – Open Plans ... https://plans.arch.ethz.ch/archives/project/alterswohnungen-seefeldstrasse- mark-ammann ... alterswohnungen-seefeldstrasse- mark-ammann – Open Plans ...
Dinaqor
8952 Schlieren, Wagistrasse 25
DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure.
Dinaqor
Wagistrasse 25
8952 Schlieren
10 Ergebnisse für "mark" unter Dinaqor
Mark Dehdashtian – DiNAQOR
... Executive Vice President, Medical Devices Mark Dehdashtian is a product development leader with ... Mark Dehdashtian – DiNAQOR ... https://www.dinaqor.com/team/ mark-dehdashtian/ ... Mark Dehdashtian – DiNAQOR ...
admindqor – DiNAQOR
... Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production ... DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to ... Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production ... DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1683 Ergebnisse für "mark" unter Somagenetix
UZH - Center for Reproducible Science - Mark Robinson
... Mark D. Robinson, Prof. Dr. Faculty of Science ... UZH - Center for Reproducible Science - Mark Robinson ... https://www.crs.uzh.ch/en/people/strg-cmte/ Mark-Robinson.html ... UZH - Center for Reproducible Science - Mark Robinson ...
UZH - Department of Communication and Media Research - Mark Eisenegger
... UZH - Department of Communication and Media Research - Mark Eisenegger ... https://www.ikmz.uzh.ch/en/department/people/professors/ mark-eisenegger.html ... UZH - Department of Communication and Media Research - Mark Eisenegger ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
962 Ergebnisse für "mark" unter University of Zurich
UZH - Institute of Molecular Life Sciences - Mark D. Robinson
... UZH - Institute of Molecular Life Sciences - Mark D. Robinson ... UZH - Institute of Molecular Life Sciences - Mark D. Robinson Home Main navigation Search Jump to ... UZH - Institute of Molecular Life Sciences - Mark D. Robinson ...
Rezension von: Mark Rowe: Bonds of the Dead - Zurich Open Repositor...
... Rezension von: Mark Rowe: Bonds of the Dead Steineck, Raji C (2013). Rezension von: Mark Rowe ... Rezension von: Mark Rowe: Bonds of the Dead - Zurich Open Repository and Archive ... Rezension von: Mark Rowe: Bonds of the Dead - Zurich Open Repository and Archive Header ... Rezension von: Mark Rowe: Bonds of the Dead - Zurich Open Repository and Archive ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
159 Ergebnisse für "mark" unter Roche Glycart AG
SARS-CoV-2 Rapid Antigen test now available in markets accepting th...
... . rdoe_login.closeText News SARS-CoV-2 Rapid Antigen test now available in markets accepting the CE mark Basel ... SARS-CoV-2 Rapid Antigen test now available in markets accepting the CE mark ... SARS-CoV-2 Rapid Antigen test now available in markets accepting the CE mark You appear to be using ... SARS-CoV-2 Rapid Antigen test now available in markets accepting the CE mark ...
Roche receives CE mark for the use of saliva samples with cobas® SA...
... rdoe_login.closeText News Roche receives CE mark for the use of saliva samples with cobas® SARS-CoV ... test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely ... Roche receives CE mark for the use of saliva samples with cobas® SARS-CoV-2 Qualitative test on ... https://diagnostics.roche.com/global/en/news-listing/2021/roche-receives-CE- mark-for-use-of-saliva ... Roche receives CE mark for the use of saliva samples with cobas® SARS-CoV-2 Qualitative test on ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
39 Ergebnisse für "mark" unter University Hospital Zurich, Research and Education Office
Slide A IV 21
... - Fehlen einer Zonierung: Rinde bzw. Mark nicht zu unterscheiden - Sehr spärlich Lymphozyten 2 3/12 ... Fibrose - Wenig Parenchym - Fehlen einer Zonierung: Rinde bzw. Mark nicht zu unterscheiden - Sehr spärlich ...
Kuros Biosciences AG
8952 Schlieren, Wagistrasse 25
+41 (0)44 733 4747
Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
19 Ergebnisse für "mark" unter Kuros Biosciences AG
Kuros BioSciences - Pipeline
... Synthetic Orthobiologics (CE Mark/510k) Fibrin/PTH Orthobiologics (NDA/MAA) * Phase II & III ... clinical study utilizing safety data from tibial shaft fracture trial Sealants (CE Mark/PMA) Wagistrasse 25 ... Kuros Biosciences’ lead product candidates. Synthetic Orthobiologics (CE Mark/510k) Fibrin/PTH ... Sealants (CE Mark/PMA) Home Disclaimer Terms & Conditions © Copyright Kuros Biosciences 2018 Kuros ...
Dr. Florence Barrère de Groot - Kuros Biosciences
... preclinical and clinical studies. – Market approval for clinical use in EU and USA (CE mark, 510k clearance ... clinical studies. – Market approval for clinical use in EU and USA (CE mark, 510k clearance). – Experience ...
CUTISS AG
8952 Schlieren, Grabenstrasse 11
+41 44 244 36 60
info@cutiss.swiss
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
CUTISS AG
Grabenstrasse 11
8952 Schlieren
18 Ergebnisse für "mark" unter CUTISS AG
2. November 2022 – CUTISS
... tissue for patients suffering from severe skin burns and injuries. Skip ahead to the 38min mark to see ... burns and injuries. Skip ahead to the 38min mark to see and hear Daniela speak. Newsroom Interview RAI ...
RAI Scuola reportage on skin and interview – CUTISS
... patients suffering from severe skin burns and injuries. Skip ahead to the 38min mark to see and hear ... severe skin burns and injuries. Skip ahead to the 38min mark to see and hear Daniela speak . Newsroom ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Wagistrasse 25
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Wagistrasse 25
8952 Schlieren
10 Ergebnisse für "mark" unter CSL Vifor
CSL Annual Report 2022 – Page 61
... companies. Mark Hill BA (Organisational Management) Executive MBA (Information Technology Management ... ) Executive Vice President, Chief Digital Information Officer Mark Hill, chief digital information officer at ... companies. Mark Hill BA (Organisational Management) Executive MBA (Information Technology Management ... ) Executive Vice President, Chief Digital Information Officer Mark Hill, chief digital information officer at ...
CSL Annual Report 2023 – Page 68
... Governance Mark Hill BA (Organisational Management) Executive MBA (Information Technology Management) Age 62 ... Executive Vice President, Chief Digital Information Officer Mark Hill, Chief Digital Information Officer at ... Annual Report 2022/23 66 10 CSL’s Governance Mark Hill BA (Organisational Management) Executive MBA ... (Information Technology Management) Age 62 Executive Vice President, Chief Digital Information Officer Mark ...
ProteoMediX AG
8952 Schlieren, Wagistrasse 23
+41 44 733 40 90
contact@proteomedix.com
ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer and the personalized treatment thereof.
ProteoMediX AG
Wagistrasse 23
8952 Schlieren